Generated by AI
BioLineRx Ltd. is a biopharmaceutical company focused on developing and commercializing therapies for oncology and hematology. Its principal product, APHEXDA (motixafortide), is used in the United States to mobilize stem cells for autologous transplantation in patients with multiple myeloma. The company also develops motixafortide for additional potential applications, including solid tumors, while maintaining a pipeline of investigational treatments designed to address cancer and related blood disorders. BioLineRx’s activities span clinical development, regulatory support, commercialization, and collaboration with healthcare and pharmaceutical partners. Based in Modi’in, Israel, the company operates within the biotechnology and medical research sector, serving specialized markets where targeted therapies and supportive treatment approaches are important to patient care. Through its focus on oncology and hematology, BioLineRx Ltd. contributes to the development of treatments for serious diseases and participates in the broader market for innovative pharmaceutical products and clinical-stage therapies.
WebsiteModi’in Technology Park
Hevel Modi'in, 7177871
Israel
The latest articles about BLRX.
Summary of Aug 31's posts. Generated by AI.
Summary of Jun 6's posts. Generated by AI.
Summary of May 30's posts. Generated by AI.
Summary of Aug 31's posts. Generated by AI.
Investors talking about BLRX also mention these. Each card shows that asset’s own numbers for the past 24 hours.